Is Covid-19 a defense to a battery charge?
July 20th 2020Dr. Joe acquired a new laser prior to the pandemic. Three patients are scheduled for treatment during which he had told them a laser expert would be present. The laser expert deferred due to COVID-19. After carrying out the procedures alone, one patient sues for battery, though there were no adverse events. Is this battery? Can Dr. Joe use COVID-19 challenges as a defense?
A ‘biomarker’ of psychiatric adverse effects with isotretinoin?
July 17th 2020While recognizing that a patient’s mental health generally improves with isotretinoin use due to improvement in acne symptoms, clinicians may consider screening for insomnia during the course of treatment, as it may be an indicator for vulnerability to side effects, researchers say.
Researchers encourage reporting on hormone therapy in acne trial demographics
July 16th 2020Many current acne clinical trials do not consider those patients already on hormone therapy, which researchers say may affect therapeutic outcomes. Authors of a recent study encourage this reporting in future studies to help clinicians better assess how the data might represent a practice population.
Nanotechnology: An opportunity to advance skin cancer treatment
July 1st 2020In cancer immunotherapy, nanoparticles can be directed to different cells and tissues related to the immune response. This technology is currently being investigated to enhance drug delivery in skin cancer therapy with the hope of promoting more robust antitumor effects and improved clinical outcomes.
No evidence of increased cancer incidence in children using topical
June 24th 2020A recent study shows no increased risk of incidence of malignancies in patients using topical tacrolimus. A black box warning on the therapy has made it challenging for physicians to prescribe, and researchers hope this evidence will lead to the FDA reconsidering that warning.
Consider lesion biopsy in patients with history of certain cancers
May 4th 2020While little is known about BPDCN and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.
Red light treatment proves safe, effective for androgenetic alopecia
April 6th 2020REVIAN Inc. releases data from their investigational study examining their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia, showing the FDA-cleared device to be both safe and effective at week 16 in a 26-week trial.